Stress-hormone blocker for anxiety research (alpha-helical CRF 12-41)
A synthetic peptide that blocks the effects of the body's main stress hormone (CRF) in animal experiments studying anxiety, fear, and appetite, used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
α-Helical CRF (12-41) is a synthetic peptide analog of the stress hormone corticotropin-releasing factor (CRF), designed to be α-helical across most of its length. It is a research tool, not a therapeutic — laboratories use it to block the effects of endogenous CRF in animal experiments on stress, anxiety, fear, feeding, and ACTH release. The closely related α-helical CRF(9-41), which extends three residues further at the N-terminus, is the form most often cited in the literature and behaves as a CRF receptor antagonist (Takao 1989; Swerdlow 1989; Adamec 1993).
The stored sequence here is FHLLREMLEMAKAEQEAEQAALNRLLLEEA (30 residues, corresponding to positions 12–41 of CRF). The acidic-amphipathic design enforces α-helix formation across the receptor-binding C-terminal segment; the N-terminal segment that drives signaling in native CRF is absent, which is what gives this analog its antagonist behavior at CRF receptors.
History
CRF was identified by Wylie Vale's group at the Salk Institute in 1981 as the hypothalamic factor that drives the pituitary stress response. α-Helical CRF(9-41) was subsequently developed as a competitive CRF receptor antagonist and became, through the late 1980s and 1990s, the standard pharmacological tool for asking "what does endogenous CRF do?" in rodent stress and behavior models. The papers cited on this card span 1987–2012 and trace that arc: from pituitary cell-column work in fish (Weld 1987) through ACTH-secretion blockade (Takao 1989), fear-potentiated startle (Swerdlow 1989), elevated plus maze anxiety (Adamec 1993), feeding behavior (Dagnault 1993; de Pedro 1997), memory retrieval (Kumar 1996), and visceral hypersensitivity in maternally separated rats (van den Wijngaard 2012).
What it does
In animal studies, α-helical CRF blocks behavioral and endocrine effects driven by CRF. Centrally administered, it has reversed CRF-induced and fear-induced potentiation of the acoustic startle response (Swerdlow 1989), reduced noradrenaline-driven ACTH secretion (Takao 1989), prevented anxiogenic effects of CRF in the elevated plus maze in both intact and hypophysectomized rats (Adamec 1993), and blocked CRF's modulation of appetitive versus aversive memory retrieval (Kumar 1996). It has also been used to probe non-classical CRF actions: blocking the anorectic effect of 17-β-estradiol (Dagnault 1993), reducing feeding in goldfish via cortisol and catecholamine pathways (de Pedro 1997), and reversing nicotine-induced conditioned (but not unconditioned) anxiety (Tucci 2003).
Two negative findings are worth flagging from the same body of work: peripherally administered α-helical CRF(9-41) did not reverse stress-induced mast-cell-dependent visceral hypersensitivity in maternally separated rats (van den Wijngaard 2012), and i.c.v. α-helical CRF did not block the vocalizations of isolated guinea pig pups (Hennessy 1992) — both suggesting the antagonist's effects are context- and route-dependent rather than universal.
Mechanism
The endogenous ligand CRF acts at two class B GPCRs, CRHR1 and CRHR2. α-Helical CRF analogs occupy the receptor's extracellular domain but lack the N-terminal residues required to trigger downstream signaling, so they function as competitive antagonists at the receptor population a given experiment recruits. The literature on this card describes effects consistent with central CRF receptor blockade (anxiety, fear, ACTH, appetite, memory). Receptor-subtype selectivity (CRHR1 versus CRHR2) is not addressed in detail by these papers — α-helical CRF(9-41) is generally considered a non-selective CRF receptor antagonist, predating the more selective small-molecule antagonists developed later.
Skórzewska and colleagues (2008, 2009) extended the picture: in rat fear-response paradigms, α-helical CRF(9-41) altered c-Fos expression and amino acid release in the central nucleus of the amygdala, implicating amygdala glutamatergic/GABAergic balance in CRF's anxiogenic action. Kask and colleagues (1997) showed that α-helical CRF(9-41) prevented the anxiogenic effect of the NPY Y1 receptor antagonist BIBP3226, suggesting CRF tone gates NPY's anxiolytic signal in rat brain.
Evidence
- Human: No human trials. This is a research-grade peptide tool, not a clinical compound.
- Animal: Extensive across rats (most papers), goldfish (Weld 1987; de Pedro 1997), and guinea pigs (Hennessy 1992). Effects include reversal of CRF- and stress-induced anxiety, ACTH suppression, feeding modulation, and memory effects.
- In vitro: Pituitary cell-column work in goldfish showed dose-dependent inhibition of CRF- and urotensin-I-stimulated ACTH release (Weld 1987); rat neurointermediate lobe preparations confirmed direct CRF-receptor interaction (Saland 1991).
Known effects (in animal models)
- Anxiolytic-like under CRF challenge — blocks CRF-induced anxiety in plus maze (Adamec 1993); reverses nicotine-induced conditioned anxiety (Tucci 2003); blocks NPY-antagonist-induced anxiogenesis (Kask 1997).
- Reduces fear-potentiated startle — both CRF-induced and fear-induced potentiation reversed (Swerdlow 1989).
- Blocks central CRF-driven ACTH secretion — when ACTH is driven by central noradrenaline (Takao 1989) or pituitary CRF stimulation (Weld 1987).
- Modulates feeding — prevents estradiol anorexia in rats (Dagnault 1993); reduces feeding in goldfish via cortisol/catecholamine pathways (de Pedro 1997).
- Affects memory retrieval — blocks CRF's differential effect on appetitive versus aversive memory (Kumar 1996).
- No effect on peripheral mast-cell-dependent visceral hypersensitivity (van den Wijngaard 2012) or isolated-pup vocalizations (Hennessy 1992) under the conditions tested.
Safety signals
No human safety data exist for α-helical CRF (12-41) or (9-41); these peptides have been used exclusively as preclinical research tools. The cited animal studies do not report systematic toxicology endpoints; they were designed to probe CRF-system pharmacology rather than to characterize safety.
Regulatory status
- US/EU: Not approved for any indication; no investigational status. Used as a research reagent only.
- WADA: Not listed by name on the prohibited list; as a non-therapeutic peptide research tool with no anabolic or performance-enhancing application described in the literature, it does not match the typical S2 (peptide hormones) profile.
Related peptides
- Native CRF (corticotropin-releasing factor) — the 41-residue endogenous ligand that α-helical CRF analogs were designed to compete with. The cited literature uses CRF and α-helical CRF as paired tools (Adamec 1993; Skórzewska 2008, 2009).
- Urotensin-I — fish CRF-family peptide that also stimulates pituitary ACTH release and is blocked by α-helical CRF(9-41) in goldfish pituitary cell columns (Weld 1987).
Notes on the stored sequence
The 30-residue stored sequence corresponds to CRF(12-41). Most of the published pharmacology cited above is on α-helical CRF(9-41), which is three residues longer at the N-terminus. The two analogs share the C-terminal α-helical receptor-binding scaffold and the antagonist mode of action, but readers comparing this card directly to a specific paper should check which numbering convention that paper used.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
If this peptide blocks both CRHR2 and CRHR1, would that change how we interpret past anxiety and stress experiments?
If researchers knew exactly which receptor is blocked, future drug design for anxiety and depression could focus on the right target, saving years of misdirected effort. Patients with stress-related disorders would benefit from clearer science guiding new therapies.
Could the three missing amino acids at the start make this peptide fall apart sooner in blood or brain fluid?
If true, researchers would know to favor the longer version for longer-lasting experiments, and drug developers would avoid wasting resources on a peptide that degrades too quickly to be useful.
If this peptide blocks one stress signal but leaves another active, could that explain why some experiments show mixed results?
If true, scientists could use this property to design drugs that reduce anxiety without unwanted side effects on metabolism or heart function, helping patients who need safer anti-stress medicines.
Could the same dose work differently in different parts of the brain because of varying salt levels?
If true, scientists would know to control for tissue environment when comparing study results, and drug developers could design formulations that keep the peptide active where it is needed most.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.6995538473129272 | openfold3-mlx |
| ranking score | 0.7755861282348633 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.771 | global PDE — lower = better |
| disorder | 0.168 | fraction disordered |
| chain pair ipTM (A, B) | 0.700 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | aedd8f3eb814e392… |
| hardware | apple_m4_base_16gb |
| mlx version | 0.31.1 |
| python | 3.14.3 |
| random seed | 42 |
| msa strategy | colabfold |
| diffusion samples | 1 |
| runtime | 331s |
| predicted by | mlx@peptide |
| predicted at | 2026-04-22 |
python3 openfold3/run_openfold.py predict --query_json {query.json} --runner_yaml examples/example_runner_yamls/mlx_runner.yml --output_dir {output_dir} --num_diffusion_samples 1 ▸citationbibtex
@peptide{pep10536,
sequence = {FHLLREMLEMAKAEQEAEQAALNRLLLEEA},
target = {crhr2},
author = {peptidemodel},
year = {2026},
status = {computed}
}